For Immediate Release
August 12, 2020
CRANFORD, NJ – WBB Securities acted as co-manager for a public offering of Omeros Corporation on August 11, 2020. Gross proceeds to Omeros from the offering are approximately $115.06 million, before deducting the underwriting discount and estimated offering expenses. Omeros intends to use the net proceeds from the Equity Offering and the remainder of the net proceeds from an accompanying Notes Offering for general corporate purposes, including funding clinical trials, pre-clinical studies, manufacturing, build-out of commercial infrastructure and other costs associated with advancing its development programs and product candidates toward regulatory submissions and potential commercialization. The offering consisted of 7.935 million common shares of Omeros common stock at a price to the public of $14.50 per share. Included were 1.035 million shares of Common Stock pursuant to the Underwriters’ option to purchase additional shares, which the Underwriters exercised in full on August 14, 2020.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About WBB Securities
WBB Securities is a leading Investment Management, Investment Banking, and Equity Research firm focused primarily in the life sciences niche. Established in 2001 with offices in San Diego, New York City and New Jersey. WBB Securities is registered with the SEC as a broker-dealer and is a member of the Financial Regulatory Authority, as well as a state registered investment advisor with a proprietary trading desk. The firm is comprised of a nationwide team of respected senior investment and research professionals serving institutional and high net-worth clients.
About Omeros, Corporation
Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. In addition to its commercial product OMIDRIA (phenylephrine and ketorolac intraocular solution) 1%/0.3%, Omeros has multiple clinical-stage development programs focused on complement-mediated disorders and substance abuse, as well as a diverse group of preclinical programs including GPR174, a novel target in immuno-oncology that modulates a new cancer immunity axis recently discovered by Omeros. Small-molecule inhibitors of GPR174 are part of Omeros’ proprietary G protein-coupled receptor (“GPCR”) platform through which it controls 54 new GPCR drug targets and their corresponding compounds. The company also exclusively possesses a novel antibody-generating platform.
